|1.||Anderson, Pete: 5 articles (05/2008 - 08/2006)|
|2.||Sartor, Oliver: 2 articles (02/2007 - 01/2004)|
|3.||Erlandson, Linda: 2 articles (08/2006 - 10/2005)|
|4.||Rodriguez, Vilmarie: 2 articles (08/2006 - 10/2005)|
|5.||Wiseman, Gregory A: 2 articles (08/2006 - 10/2005)|
|6.||Anderson, Peter M: 2 articles (08/2006 - 10/2005)|
|7.||Doschak, M R: 1 article (11/2015)|
|8.||Cooper, D M L: 1 article (11/2015)|
|9.||Pushie, M J: 1 article (11/2015)|
|10.||Yang, Y: 1 article (11/2015)|
|1.||Neoplasm Metastasis (Metastasis)
02/01/2007 - "Samarium Sm 153 lexidronam (Sm-153) is an effective and well-tolerated treatment for painful bone metastases. "
11/01/2009 - "Phase I trial of vertebral intracavitary cement and samarium (VICS): novel technique for treatment of painful vertebral metastasis."
10/01/2011 - "Adverse events in the long-term follow-up of patients treated with samarium Sm 153 lexidronam for osseous metastases."
08/01/2009 - "In this first report, we describe our experience of use of Samarium EDTMP in conjunction with biphosphonates in a haemodialysis patient for treatment of painful bone metastasis. "
08/01/1998 - "[Analgesic response and secondary effects in patients with osteoblastic metastasis, treated with Samarium 153 ethylenediaminotetramethylenephosphate]."
01/01/2009 - "These retrospective study is aimed to evaluate the efficacy of therapy with Stronthium-chloride 89 (89SrCl) and Samarium 153 conjugated with ethylenediaminetetramethylene phosphonic acid (153Sm-EDTMP) in the palliation of bone pain due to metastatic malignancy. "
02/01/2007 - "Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain."
10/01/2014 - "Samarium-treated patients needed less or not at all pain killers, having a better cost-effective result."
03/01/2007 - "Of the patients, 15.4% were not in pain at rest or on movement at baseline and continued to be free of pain 4 weeks after the administration of samarium. "
03/01/2007 - "Incident pain and analgesic consumption decrease after samarium infusion: a pilot study."
06/15/2007 - "Of the 32 dogs with appendicular tumors, 20 (63%) had an improvement in the severity of lameness 2 weeks after administration of the first dose of radioactive samarium, 8 (25%) had no change in the severity of lameness, and 4 (12%) had a worsening. "
06/01/2012 - "To evaluate samarium Sm 153 lexidronam ((153)Sm-EDTMP) as a treatment option for dogs with bony tumors of the skull. "
06/01/2012 - "Use of samarium Sm 153 lexidronam for the treatment of dogs with primary tumors of the skull: 20 cases (1986-2006)."
06/15/2007 - "To evaluate survival times and palliative effects associated with the use of samarium Sm 153 lexidronam in dogs with primary bone tumors. "
06/15/2007 - "Samarium Sm 153 lexidronam for the palliative treatment of dogs with primary bone tumors: 35 cases (1999-2005)."
|4.||Prostatic Neoplasms (Prostate Cancer)
09/01/2000 - "Successful use of Samarium 153 for emergency treatment of disseminated intravascular coagulation due to metastatic hormone refractory prostate cancer."
06/01/2005 - "To evaluate the cost-effectiveness of samarium [153Sm-EDTMP] (Quadramet) compared to conventional therapy in the treatment of pain in patients with prostate cancer and bone metastases. "
03/01/2009 - "This study assessed whether baseline and short-term patient-reported quality of life (QOL) differs in patients with symptomatic metastatic prostate cancer undergoing palliative management using opioids, nonsteroidal anti-inflammatory agents (NSAIDs), (89)strontium chloride ((89)Sr), and samarium-lexidronam ((153)Sm). "
|1.||Non-Steroidal Anti-Inflammatory Agents (NSAIDs)
|2.||Opioid Analgesics (Opioids)
|4.||strontium chloride (strontium chloride Sr 89)
|6.||samarium ethylenediaminetetramethylenephosphonate (Quadramet)
|1.||Palliative Care (Palliative Medicine)
|3.||Drug Therapy (Chemotherapy)
|4.||Hematopoietic Stem Cell Transplantation